Your browser doesn't support javascript.
loading
Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial.
Webb, Jamie; Peerbux, Sarrah; Smittenaar, Peter; Siddiqui, Sarim; Sherwani, Yusuf; Ahmed, Maroof; MacRae, Hannah; Puri, Hannah; Bhalla, Sangita; Majeed, Azeem.
Afiliación
  • Webb J; Digital Therapeutics Inc, San Francisco, CA, United States.
  • Peerbux S; Imperial College London, London, United Kingdom.
  • Smittenaar P; Digital Therapeutics Inc, San Francisco, CA, United States.
  • Siddiqui S; Digital Therapeutics Inc, San Francisco, CA, United States.
  • Sherwani Y; Digital Therapeutics Inc, San Francisco, CA, United States.
  • Ahmed M; Digital Therapeutics Inc, San Francisco, CA, United States.
  • MacRae H; Digital Therapeutics Inc, San Francisco, CA, United States.
  • Puri H; Digital Therapeutics Inc, San Francisco, CA, United States.
  • Bhalla S; Digital Therapeutics Inc, San Francisco, CA, United States.
  • Majeed A; Imperial College London, London, United Kingdom.
JMIR Ment Health ; 7(10): e22833, 2020 Oct 06.
Article en En | MEDLINE | ID: mdl-33021488
ABSTRACT

BACKGROUND:

Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

OBJECTIVE:

Our objective was to test the preliminary effectiveness of Quit Genius, a novel digital therapeutic intervention for smoking cessation.

METHODS:

A 2-arm, single-blinded, parallel-group randomized controlled trial design was used. Participants were recruited via referrals from primary care practices and social media advertisements in the United Kingdom. A total of 556 adult smokers (aged 18 years or older) smoking at least 5 cigarettes a day for the past year were recruited. Of these, 530 were included for the final analysis. Participants were randomized to one of 2 interventions. Treatment consisted of a digital therapeutic intervention for smoking cessation consisting of a smartphone app delivering cognitive behavioral therapy content, one-to-one coaching, craving tools, and tracking capabilities. The control intervention was very brief advice along the Ask, Advise, Act model. All participants were offered nicotine replacement therapy for 3 months. Participants in a random half of each arm were pseudorandomly assigned a carbon monoxide device for biochemical verification. Outcomes were self-reported via phone or online. The primary outcome was self-reported 7-day point prevalence abstinence at 4 weeks post quit date.

RESULTS:

A total of 556 participants were randomized (treatment n=277; control n=279). The intention-to-treat analysis included 530 participants (n=265 in each arm; 11 excluded for randomization before trial registration and 15 for protocol violations at baseline visit). By the quit date (an average of 16 days after randomization), 89.1% (236/265) of those in the treatment arm were still actively engaged. At the time of the primary outcome, 74.0% (196/265) of participants were still engaging with the app. At 4 weeks post quit date, 44.5% (118/265) of participants in the treatment arm had not smoked in the preceding 7 days compared with 28.7% (76/265) in the control group (risk ratio 1.55, 95% CI 1.23-1.96; P<.001; intention-to-treat, n=530). Self-reported 7-day abstinence agreed with carbon monoxide measurement (carbon monoxide <10 ppm) in 96% of cases (80/83) where carbon monoxide readings were available. No harmful effects of the intervention were observed.

CONCLUSIONS:

The Quit Genius digital therapeutic intervention is a superior treatment in achieving smoking cessation 4 weeks post quit date compared with very brief advice. TRIAL REGISTRATION International Standard Randomized Controlled Trial Number (ISRCTN) 65853476; https//www.isrctn.com/ISRCTN65853476.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Revista: JMIR Ment Health Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 Problema de salud: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Tipo de estudio: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Revista: JMIR Ment Health Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
...